Celldex Therapeutics, Inc. (CLDX) Financial Statements
Celldex Therapeutics, Inc. (CLDX) reported trailing twelve-month revenue of $158000 (down 97.3% year on year) and net income of -$300.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$242.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CLDXCelldex Therapeutics, Inc.Follow CLDX — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.3 | 11.2 | 4.1 | 3.6 | 5.5 | 6.8 | 12.7 | 9.5 | 3.6 | 7.4 | 4.7 | 2.4 | 6.9 | 7.0 | 1.5 | 0.2 | |
| Gross profit | — | — | — | — | — | — | — | 8.8 | 3.5 | 7.2 | 4.6 | 2.3 | 6.6 | 6.8 | 1.3 | — | |
| Research & development | 32.4 | 47.4 | 67.4 | 104.4 | 100.2 | 102.7 | 96.2 | 66.4 | 42.7 | 42.5 | 53.3 | 82.3 | 118.0 | 163.6 | 245.1 | 278.8 | |
| Operating income | -43.4 | -58.1 | -81.4 | -122.4 | -129.5 | -132.9 | -121.5 | -156.4 | -55.0 | -63.4 | -71.2 | -115.2 | -154.5 | -195.1 | -287.4 | -325.8 | |
| Pre-tax income | -44.8 | — | — | — | -127.2 | -128.5 | -117.3 | -151.9 | -50.9 | -60.9 | -70.7 | -112.3 | -141.4 | -157.9 | -258.8 | -300.5 | |
| Income tax | — | 0.0 | 0.0 | — | — | — | -24.3 | -0.8 | — | -1.2 | -0.2 | — | 0.0 | 0.0 | 0.0 | — | |
| Net income | -44.8 | -59.1 | -81.6 | -118.1 | -127.2 | -128.5 | -93.0 | -151.2 | -50.9 | -59.8 | -70.5 | -112.3 | -141.4 | -157.9 | -258.8 | -300.5 | |
| Diluted EPS ($) | -1.13 | -1.02 | -1.02 | -1.32 | -1.31 | -18.99 | -10.86 | -14.48 | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 | -3.86 | |
| Diluted shares (mn) | 39.5 | — | — | — | — | — | — | — | 14.5 | 29.6 | 42.9 | 46.9 | 48.4 | 64.4 | 66.4 | — |
USD millions · SEC XBRL
Celldex Therapeutics, Inc. — questions
- What is Celldex Therapeutics, Inc.'s revenue?
- $158000 over the twelve months to 2026-06-30, down 97.3% year on year, from its 10-Q and 10-K filings.
- What is Celldex Therapeutics, Inc.'s net income?
- -$300.5M over the twelve months to 2026-06-30.
- What is Celldex Therapeutics, Inc.'s free cash flow?
- -$242.1M over the twelve months to 2026-06-30.
- What are Celldex Therapeutics, Inc.'s diluted earnings per share?
- $-3.86 over the twelve months to 2026-06-30.
Every figure on this page comes from Celldex Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.